tirzepatide for the treatment of obstructive sleep apnea and obesity Original Article: (SURMOUNT-OSA) buff.ly/4ccuPKO Editorial: Entering a New Era in Sleep-Apnea Treatment buff.ly/3XyX1D2 Prior authorization isn't supposed to

One of the most significant outcomes of the study is the reduction in non-fatal strokes, which are often precursors to more severe cardiovascular events

After 6 months of therapy, those taking GLP1 drugs showed: Elevated risk of androgenic alopecia Elevated risk of nonscarring hair loss No significant change in telogen effluvium risk No significant change in alopecia areata risk At the 12-month mark, the pattern had shifted slightly: Continued higher risk for androgenic alopecia Continued higher risk for nonscarring hair loss A newly increased risk of telogen effluvium Still no change in risk of alopecia areata The apparent absence of a link between GLP1 medications and alopecia areata is especially notable, as isolated case reports have previously suggested an association

Response: We thank the commenters for their feedback on these issues, including the importance of antimicrobial stewardship

Running low

You can revoke an already given consent at any time